Jointly provided by Postgraduate Institute for Medicine and the
International Association of Providers of AIDS Care
This activity is supported by an independent educational grant
from Merck & Co., Inc.
This activity has been designed to meet the educational needs of physicians working in the field of HIV medicine.
In 2015, a global consensus solidified around the goal of ending AIDS as a public health threat by 2030. Major tools in achieving these goals are attaining global HIV testing, treatment, and viral suppression targets articulated in the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets, which call for ensuring that by 2020:
These goals and the clinical and public health consensus around them are based on two clinical concepts that by the end of 2015 had achieved universally accepted clinical validation. These concepts are treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). TasP is the idea that HIV-positive persons whose virus is suppressed on ART are extremely unlikely to transmit HIV to sex and drug partners. PrEP is the use of ART by uninfected individuals to prevent HIV infection from sexual contact with an HIV-infected partner. Both of these concepts have been clinically validated in a number of large, randomized, controlled clinical trials.
TasP and PreP, then, join HIV testing as the three clinical pillars supporting current strategies to curb and eventually eliminate HIV and AIDS. Behavioral, clinical, and structural interventions to expand the use of PrEP and the achievement of TasP (that is, increasing the proportion of HIV-positive persons who are in care, on ART, and with virologic suppression) are integral to achieving the globally accepted goal of ending the epidemic in the next two decades.
Unfortunately, while TasP and PrEP are widely accepted among expert physicians and public health leaders who understand these concepts and the evidence supporting them, many physicians and allied healthcare professionals who care for people living with HIV and manage the care of patients at high risk for HIV infection do not know enough about TasP and PrEP to utilize these invaluable tools widely enough in their own clinical settings. Nor do public health policies in all countries currently support widespread access to PrEP, despite the definitive evidence of its success.
Evidence-based education can make an invaluable and measurable contribution toward enhancing HIV treatment and prevention outcomes at individual, community, and public health levels. By participating in evidence-based educational programs, physicians can increase the knowledge and improve their implementation of best-practice approaches to help drive consistent quality of care, reduce the incidence of new infections, reduce morbidity and mortality among HIV-positive patients, and improve cost-effectiveness of medical interventions. The considerable time, effort, and organization needed to clinically validate TasP and PrEP provides an imperative to gain the maximum utility from their implementation. It is thus important to conduct education about these strategies so that they are used appropriately.
This online activity features:
After completing this activity, participants will be able to:
Benjamin Young, MD, PhD
Vice President/Chief Medical Officer
International Association of Providers of AIDS Care
Denver, CO, USA
This activity is accredited as a continuing education activity for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Association of Providers of AIDS Care. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Benjamin Young, MD, PhD||Grant/Research Support: Gilead Sciences, ViiV Healthcare; Consultant/Advisor: Bristol-Myers Squibb, Merck & Co., ViiV Healthcare; Speaker’s Bureau: Merck & Co.; Advisory Board: Bristol-Myers Squibb, Gilead Sciences, Merck & Co., ViiV Healthcare|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Initial Release Date: September 1, 2016 Expiration Date: September 30, 2017
The estimated time to complete this activity is 1 hour. There are no fees for participating and receiving CME credit for this activity. During the period September 1, 2016 through September 30, 2017 participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 10258. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For questions related to the accreditation of this activity, please contact the Postgraduate Institute for Medicine (www.pimed.com).